Adaptive Biotechnologies's top three insider shareholders as of March 23, 2026 are Chad M Robins (Ceo And Chairman, 2.77Mn shares), Harlan S Robins (Chief Scientific Officer, 1.99Mn shares), Julie Rubinstein (President And Coo, 643.47K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Chad M Robins | Ceo And Chairman | 2,301,113 | 0 | 13 Mar, 2026 |
| Harlan S Robins | Chief Scientific Officer | 1,522,058 | 0 | 13 Mar, 2026 |
| Tycho Peterson | Chief Financial Officer | 531,553 | 0 | 06 Mar, 2024 |
| Julie Rubinstein | President And Coo | 481,906 | 0 | 23 Mar, 2026 |
| Susan Bobulsky | Chief Commercial Officer, Mrd | 427,775 | 0 | 13 Mar, 2026 |
| Francis Lo | Chief People Officer | 291,374 | 0 | 13 Mar, 2026 |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | 272,751 | 0 | 13 Mar, 2026 |
| Kyle Piskel | Chief Financial Officer | 259,840 | 0 | 13 Mar, 2026 |
| Peter M Neupert | 240,315 | 0 | 06 Mar, 2026 | |
| Nitin Sood | Chief Commercial Officer, Mrd | 214,808 | 0 | 08 Aug, 2023 |
| Stacy L Taylor | Svp And General Counsel | 139,365 | 0 | 23 Aug, 2024 |
| Katey Einterz Owen | 88,254 | 0 | 06 Mar, 2026 | |
| Michael J Pellini | 69,690 | 0 | 06 Mar, 2025 | |
| Robert Hershberg | 62,347 | 0 | 06 Mar, 2026 | |
| Henning Thorsen | Svp, Commercial Operations | 29,061 | 0 | 19 May, 2021 |
| Leslie Trigg | 25,907 | 0 | 08 Mar, 2023 | |
| Kevin T Conroy | 22,968 | 0 | 08 Mar, 2023 | |
| Chad M Cohen | Chief Financial Officer | 21,604 | 0 | 23 Dec, 2021 |
| Lance Baldo | Chief Medical Officer | 17,171 | 0 | 10 Mar, 2022 |
| Michelle Renee Griffin | 15,625 | 0 | 13 Mar, 2026 | |
| Jyoti Palaniappan | Svp, Diagnostics, T Detect | 9,158 | 0 | 19 Jul, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 19 Mar, 2026 | Julie Rubinstein | Common Stock | A | 14,722 | $6.55 | 509,642 | D | M |
| 19 Mar, 2026 | Julie Rubinstein | Common Stock | D | 19,060 | $13.18 | 490,582 | D | S |
| 20 Mar, 2026 | Julie Rubinstein | Common Stock | A | 3,939 | $6.55 | 494,521 | D | M |
| 20 Mar, 2026 | Julie Rubinstein | Common Stock | A | 10,783 | $7.27 | 505,304 | D | M |
| 20 Mar, 2026 | Julie Rubinstein | Common Stock | D | 19,060 | $13.37 | 486,244 | D | S |
| 23 Mar, 2026 | Julie Rubinstein | Common Stock | A | 14,722 | $7.27 | 500,966 | D | M |
| 23 Mar, 2026 | Julie Rubinstein | Common Stock | D | 19,060 | $13.83 | 481,906 | D | S |
| 19 Mar, 2026 | Julie Rubinstein | Stock Option (right to buy) | D | 14,722 | $0.00 | 3,939 | D | M |
| 20 Mar, 2026 | Julie Rubinstein | Stock Option (right to buy) | D | 3,939 | $0.00 | 0 | D | M |
| 20 Mar, 2026 | Julie Rubinstein | Stock Option (right to buy) | D | 10,783 | $0.00 | 214,217 | D | M |
| 23 Mar, 2026 | Julie Rubinstein | Stock Option (right to buy) | D | 14,722 | $0.00 | 199,495 | D | M |
| 16 Mar, 2026 | Julie Rubinstein | Common Stock | A | 14,722 | $6.55 | 522,656 | D | M |
| 16 Mar, 2026 | Julie Rubinstein | Common Stock | D | 19,060 | $13.41 | 503,596 | D | S |
| 17 Mar, 2026 | Julie Rubinstein | Common Stock | A | 14,722 | $6.55 | 518,318 | D | M |
| 17 Mar, 2026 | Julie Rubinstein | Common Stock | D | 19,060 | $13.40 | 499,258 | D | S |
| 18 Mar, 2026 | Julie Rubinstein | Common Stock | A | 14,722 | $6.55 | 513,980 | D | M |
| 18 Mar, 2026 | Julie Rubinstein | Common Stock | D | 19,060 | $13.18 | 494,920 | D | S |
| 16 Mar, 2026 | Julie Rubinstein | Stock Option (right to buy) | D | 14,722 | $0.00 | 48,105 | D | M |
| 17 Mar, 2026 | Julie Rubinstein | Stock Option (right to buy) | D | 14,722 | $0.00 | 33,383 | D | M |
| 18 Mar, 2026 | Julie Rubinstein | Stock Option (right to buy) | D | 14,722 | $0.00 | 18,661 | D | M |